Targeted Therapy in Translational Cancer Research.

Intro -- Translational Oncology -- Title Page -- Copyright -- List of Contributors -- Series Foreword -- Foreword -- Preface: Bench to Bedside and Back -- PART I: Principles of Targeted Therapies -- CHAPTER 1: Toward Personalized Therapy for Cancer -- Introduction -- Personalized Targeted Therapy -- Prognostic Stratification and Prediction of Chemotherapy Benefit in Hormone Receptor-Positive Breast Cancer -- HER2-Targeted Therapy in Breast Cancer -- BRAF Inhibitors in BRAF Mutant Melanoma -- Strategies for Comprehensive Molecular Characterization -- A Personalized Approach to Investigational Therapy Selection -- Challenges to Personalized Cancer Therapy -- Summary -- References -- CHAPTER 2: Combining Targeted Therapies -- Rationale for Drug Combination of Targeted Agents -- Principles and Strategies for Combining Agents Targeting Signaling Pathways -- Combining Targeted and Immune Therapies -- Preliminary Data: Building the Hypothesis and Rationale for the Trial -- First Step, Regulatory Issues to Consider Before a Hands-On Approach -- Clinical Scenarios and Clinical Trial Design -- Conclusions -- References -- CHAPTER 3: Principles of Targeted Immunotherapy -- Introduction -- Principles of Immunotherapy -- Conclusion -- References -- CHAPTER 4: Cancer Stem Cell Principles -- Background -- Historical Perspective -- Cancer Stem Cells in Hematologic Malignancies -- Cancer Stem Cells in Solid Tumors -- Controversy and Clinical Relevance -- Targeting Cancer Stem Cells -- Conclusions -- Note -- References -- CHAPTER 5: The Tumor Microenvironment as a Target for Therapeutic Intervention -- Introduction -- Components of the TME -- Complex Communication Between Tumor Cells and Their Microenvironment -- Lessons Learned and Conclusions -- Final Remarks -- Acknowledgment -- References -- CHAPTER 6: The Role of Angiogenesis in Cancer.

How Vessels Are Formed -- Angiogenesis Pathways -- Therapies Targeting the VEGF Pathway -- Toxicities -- Resistance to Antiangiogenic Therapy -- Biomarkers -- Concluding Remarks -- References -- CHAPTER 7: Epigenetics and Epigenetic Therapy of Cancer -- Structure of the Genetic Code -- DNA Methylation -- DNA Demethylation -- TET Proteins -- Histone Modifications -- Noncoding RNA -- Polycomb Repressive Complex -- IDH1/2 -- Epigenetic Perturbations in Hematologic Malignancies -- Epigenetic Perturbations in Breast Cancer -- Epigenetic Perturbations in Lung Cancer -- Epigenetic Perturbations in Colon Cancer -- Epigenetics in Diagnostics -- Role of Epigenetics in Therapeutics -- Histone Deacetylase Inhibitors -- EZH2 Inhibitors -- Conclusions -- References -- CHAPTER 8: The Role of microRNAs in Cancer -- Introduction -- miRNAs Dysregulation in Cancer -- miRNAs in Therapy -- Conclusion -- References -- CHAPTER 9: Acute Myeloid Leukemia -- Introduction -- Monoclonal Antibodies -- Targeting Drivers of Proliferation in AML -- Targeting Apoptotic Pathways, Cell Cycle Regulation, and Cancer Cell Metabolism -- Chimeric Antigen Receptors and Vaccines -- Summary -- References -- CHAPTER 10: Targeted and Functional Imaging -- Introduction -- Functional Imaging of Tumor Physiology -- Functional Imaging of Tumor Molecular Targets and Processes -- Conclusion -- Note -- References -- PART II: Targeted Therapy in Hematological Malignancies -- CHAPTER 11: Targeted Therapies in Chronic Myeloid Leukemia -- Introduction -- CML Frontline Treatment Options -- Other Strategies -- Choice of Frontline Therapy -- Management of TKI Resistance -- Second Generation TKI -- Third Generation TKI -- Definition of Response and Failure to TKI Therapy and Choice of Therapy -- Can TKIs Be Safely Discontinued? -- Conclusions and Future Perspectives -- References.

CHAPTER 12: Targeted Therapy for Acute Lymphoblastic Leukemia -- Introduction -- Prognostication in ALL -- Surface Antigen as a Therapeutic Target -- BCR-ABL-Positive ALL -- Ph-Like ALL -- PI3K/AKT/mTOR Signaling Pathway Inhibitors and B-Cell Receptor Inhibitors -- Chimeric Antigen Receptor Therapy -- T-Cell ALL -- Notch Inhibition in T-Cell ALL -- Early T-Cell Precursor ALL -- Conclusions -- References -- CHAPTER 13: Chronic Lymphocytic Leukemia -- Background -- Biologic and Molecular Aspects of CLL -- Targeted Therapeutic Agents in the Treatment of CLL -- Clinical Results with BCR Signaling Kinase Inhibitors -- Other Novel Therapeutic Agents in CLL -- Conclusions -- References -- CHAPTER 14: Multiple Myeloma -- MM as a Neoplastic Factory of Immunoglobulins: Biologic and Clinical Implications -- A Broader View: MM in the Context of the BM Niche -- Distinct Molecular Targets of MM Cells -- Conclusions and Future Perspective -- References -- CHAPTER 15: The Impact of Genomics on Targeted Therapy in Multiple Myeloma and Lymphomas -- Genomics of Hematologic Neoplasms and Their Potential to Inform Rationale Therapies -- Targeted Agents in Clinical Trials for Patients with MM and DLBCL -- New Therapeutic Challenges Revealed by Genomics -- References -- CHAPTER 16: Targeted Therapy in Myelodysplastic Syndromes -- Biological Hallmarks of Myelodysplasia -- Current Standard of Care in MDS -- New Therapeutic Targets in MDS -- Conclusions -- References -- CHAPTER 17: Lymphoma and Targeted Therapies -- Overview -- Summary -- References -- PART III: Targeted Therapy in Solid Tumors -- CHAPTER 18: Targeted Therapy in Solid Tumors: Brain -- Introduction -- Predictive and Prognostic Factors -- Targets for Therapy -- Future Perspectives -- Concluding Remarks -- References -- CHAPTER 19: Targeted Therapy for Breast Cancer -- Targeting ER in Breast Cancer.

Targeting HER2 in Breast Cancer -- Novel Targeted Treatments in ER Positive Breast Cancer -- BRCA-Associated Tumors and PARP Inhibitors -- Genomic Profiling -- References -- CHAPTER 20: Targeted Therapy in Solid Tumors: Colorectal Cancer -- Overview -- Targeted Therapy, Receptors, and Signaling Networks -- Conclusion -- References -- CHAPTER 21: Endometrial Cancer -- Endometrial Cancer -- PI3K/PTEN/AKT/mTOR -- EGFR and HER2 -- IGF-1R -- FGFR2 -- E-cadherin -- Conclusions -- References -- CHAPTER 22: Targeted Therapy in Solid Tumors: Head and Neck -- Introduction -- Genetic Alterations in Head and Neck Squamous Cell Carcinoma -- Current Treatment for Head and Neck Squamous Cell Carcinoma -- Targeted Therapy in Head and Neck Squamous Cell Carcinoma -- Targeting the Epidermal Growth Factor Receptor -- Targeting the Vascular Endothelial Growth Factor Receptor -- Targeting the Proteasome -- Targeting TP53a -- Conclusions -- References -- CHAPTER 23: Targeted Therapy in Solid Tumors: Lung Cancer -- Angiogenesis -- Epidermal Growth Factor Receptor -- ALK -- ROS1 -- RET -- BRAF -- HER2 -- KRAS -- Other Mutations in Adenocarcinomas -- Squamous Cell Lung Cancer -- Comprehensive Genomic Studies -- Future Perspectives -- References -- CHAPTER 24: Targeted Therapy in Melanoma -- Introduction -- The MAP Kinase Pathway -- BRAF as a Therapeutic Target -- Paradoxical MAP Kinase Pathway Activation -- MEK Inhibitors in BRAF-Mutant Melanoma -- NRAS -- CKIT -- Acquired Resistance to BRAF-Targeted Therapy -- Mechanisms of de novo BRAF Inhibitor Resistance -- Intersection Between Targeted Therapy and Immune Therapy -- Summary -- References -- CHAPTER 25: Ovarian Cancer -- Introduction -- Ovarian Cancer Histology -- Molecular Aberrations in Ovarian Cancer -- Targeting Angiogenesis -- Targeting DNA Repair with Poly-ADP-Ribose Polymerase Inhibition.

Targeting the RAS/RAF Pathway -- Targeting the PI3K/AKT Pathway -- Targeting the Epidermal Growth Factor Receptor Pathway -- Targeting Folate -- Targeting Other Pathways of Interest -- Conclusion -- References -- CHAPTER 26: Molecular Therapeutics: Pancreatic Cancer -- Introduction -- Therapeutics Currently in Development -- Conclusions -- References -- CHAPTER 27: Targeted Therapies for Pediatric Solid Tumors -- Introduction -- Neuroblastoma -- Gliomas -- Osteosarcoma -- Ewing's Sarcoma -- Rhabdomyosarcoma -- Wilms' Tumor -- Hepatoblastoma -- Ependymomas -- Medulloblastoma -- Retinoblastoma -- Conclusions -- References -- CHAPTER 28: Prostate Cancer -- Introduction -- Molecular Pathogenesis of Prostate Cancer -- Systemic Prostate Cancer Treatments Targeting Androgen Signaling -- Non-androgen Signaling-Targeted Systemic Treatments -- Bone-Targeted Systemic Treatments -- Immunotherapy -- Future Perspectives -- References -- CHAPTER 29: Renal Cell Carcinoma and Targeted Therapy -- Introduction -- Molecular Pathogenesis of RCC -- Important Signaling Pathways in RCC -- Targeted Therapies in RCC -- Conclusion -- References -- CHAPTER 30: Targeted Therapy in Solid Tumors: Sarcomas -- Introduction -- KIT -- Conclusion -- References -- PART IV: Targeted Therapy for Specific Molecular Aberrations -- CHAPTER 31: RAS-RAF-MEK Pathway: Aberrations and Therapeutic Possibilities -- Introduction -- The RAS Family: HRAS, KRAS, and NRAS -- The Congenital RAS-opathies: Germline Mutations of RAS -- The Acquired RAS-opathies: Melanoma and NRAS -- The RAF Family: ARAF, BRAF, and CRAF -- BRAF Inhibitors -- Management of Metastatic Melanoma in the Era of BRAF Inhibitors -- The CRAF Story -- MEK Inhibitors-The MEK Family: MEK1 and MEK2 -- Future Directions: Big Results for Small Molecules -- References.

CHAPTER 32: The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.